126 related articles for article (PubMed ID: 24993333)
1. Expert consensus for postmarketing Chinese medicine intensive hospital safety monitoring.
Liao X; Zhang W; Xie YM; Tian F; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W
Chin J Integr Med; 2014 Jul; ():. PubMed ID: 24993333
[TBL] [Abstract][Full Text] [Related]
2. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
[TBL] [Abstract][Full Text] [Related]
3. Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China.
Li J; Li M; Li L; Ma L; Cao A; Wen A; Chen W; Li L; Liang Y; Deng J
BMC Pharmacol Toxicol; 2022 Jul; 23(1):51. PubMed ID: 35842685
[TBL] [Abstract][Full Text] [Related]
4. [Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine].
Xie YM; Liao X; Jiang JJ; Zhang YL; Ma R; Zhu MJ; Zhan SY; Liu JP; Liu J; Wen ZH; Yang ZQ; He Y; Li XL
Zhongguo Zhong Yao Za Zhi; 2019 Jul; 44(14):2896-2901. PubMed ID: 31602831
[TBL] [Abstract][Full Text] [Related]
5. Drug safety surveillance in China and other countries: a review and comparison.
Du W; Guo JJ; Jing Y; Li X; Kelton CM
Value Health; 2008 Mar; 11 Suppl 1():S130-6. PubMed ID: 18387057
[TBL] [Abstract][Full Text] [Related]
6. [Post-marketing safety surveillance of Diemailing Kudiezi injection: real world study in 30 233 cases].
Liao X; Yu DD; Xie YM; Zhang YL; He Y; Zhang Y; Liu Y; Yi DH; Wang YY
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2857-2863. PubMed ID: 29139248
[TBL] [Abstract][Full Text] [Related]
7. Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting.
He Y; Gao XM; Li L; Liu XG; Liu W; Hong XJ; Huang BH; Yang HL; Xue MH; Wu XJ; Liu JF
Curr Med Res Opin; 2020 Dec; 36(12):1947-1953. PubMed ID: 33016133
[TBL] [Abstract][Full Text] [Related]
8. [Data-mining characteristics of adverse drug reactions and pharmacovi-gilance of Chinese patent drugs including Aconitum herbs].
Zhang XM; Li F; Zhang B; Chen XF; Piao JZ
Zhongguo Zhong Yao Za Zhi; 2018 Jan; 43(2):216-221. PubMed ID: 29552835
[TBL] [Abstract][Full Text] [Related]
9. Adverse drug event reporting in intensive care units: a survey of current practices.
Kane-Gill SL; Devlin JW
Ann Pharmacother; 2006; 40(7-8):1267-73. PubMed ID: 16849619
[TBL] [Abstract][Full Text] [Related]
10. [A postmarketing surveillance study on 31,724 patients using Dengzhan Xixin injection in hospital].
Li YY; Lei L; Xie YM
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4757-61. PubMed ID: 27245018
[TBL] [Abstract][Full Text] [Related]
11. Chinese-Named Entity Recognition From Adverse Drug Event Records: Radical Embedding-Combined Dynamic Embedding-Based BERT in a Bidirectional Long Short-term Conditional Random Field (Bi-LSTM-CRF) Model.
Wu H; Ji J; Tian H; Chen Y; Ge W; Zhang H; Yu F; Zou J; Nakamura M; Liao J
JMIR Med Inform; 2021 Dec; 9(12):e26407. PubMed ID: 34855616
[TBL] [Abstract][Full Text] [Related]
12. [Expert consensus on the design and implementation of clinical safety centralized monitoring study of Chinese medical injection].
Zhang JH; Ren JT; Hu JQ; Xie YM; Song HB; Zhu MJ; Gao R; Wang Z; Zheng WK; Li XL; Jiang M; Huang YH; Lu F; He LY; Lian WX; Yang ZQ; Yuan WA; Hu SY; Wang BH; Wang WL; Ren DQ; Zhang BL; ;
Zhongguo Zhong Yao Za Zhi; 2017 Jan; 42(1):6-9. PubMed ID: 28945018
[TBL] [Abstract][Full Text] [Related]
13. To establish a body of evidence on safety for postmarketing Chinese medicine: A new research paradigm.
Liao X; Xie YM; Robinson N; Wang YY
Chin J Integr Med; 2017 Mar; 23(3):226-232. PubMed ID: 27900605
[TBL] [Abstract][Full Text] [Related]
14. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug events in an intensive care unit of a university hospital.
Reis AM; Cassiani SH
Eur J Clin Pharmacol; 2011 Jun; 67(6):625-32. PubMed ID: 21246350
[TBL] [Abstract][Full Text] [Related]
16. Methodological approaches to developing and establishing the body of evidence on post-marketing Chinese medicine safety.
Liao X; Robinson N
Chin J Integr Med; 2013 Jul; 19(7):494-7. PubMed ID: 23818200
[TBL] [Abstract][Full Text] [Related]
17. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
[TBL] [Abstract][Full Text] [Related]
18. Adverse Drug Events and Reactions Managed by Medical Toxicologists: an Analysis of the Toxicology Investigators Consortium (ToxIC) Registry, 2010-2016.
Beauchamp GA; Amaducci A; Greenberg MR; Meyers M; Cook M; Cannon RD; Katz KD; Finkelstein Y;
J Med Toxicol; 2019 Oct; 15(4):262-270. PubMed ID: 31309522
[TBL] [Abstract][Full Text] [Related]
19. [Clinical safety imtensive hospital monitoring on Shenfu injection with 30 106 cases].
Wang ZF; Yu JY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2871-2876. PubMed ID: 29139250
[TBL] [Abstract][Full Text] [Related]
20. Postmarketing Safety Surveillance and Reevaluation of Danhong Injection: Clinical Study of 30888 Cases.
Li XL; Tang JF; Li WX; Li CX; Zhao T; Zhao BC; Wang Y; Zhang H; Chen XF; Xu T; Zhu MJ
Evid Based Complement Alternat Med; 2015; 2015():610846. PubMed ID: 26508981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
